Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer

Purpose of investigation: HE4 (human epididymis protein 4) is suggested to be used as a potential new biomarker to identify ovarian malignancies from benign adnexal masses. The aim of this study was to evaluate HE4, in comparison with CA125 and Risk of Ovarian Malignancy Algorithm (ROMA) index in benign gynecological diseases and ovarian cancer, and additionally to determine the reference range for HE4 in healthy Turkish women. Materials and Methods: CA125 and HE4 serum levels were determined in 96 patients with benign gynecological diseases, 47 patients with ovarian cancer and 106 healthy women using a specific analyzer. CA125 and HE4 cut-offs were 35 U/ml and 70 pmol/L, respectively. Results: HE4 had significantly higher concentrations in ovarian cancer than benign gynecologic disorders (p < 0.005). Tumor marker sensitivity in ovarian cancer was 78% for HE4, 63% for CA125, and 88% for ROMA index at 95% specificity. A significantly higher area under the Receiver operator characteristic (ROC) curve was obtained with HE4 and ROMA index than CA125 in the differential diagnosis of benign gynecological diseases versus ovarian cancer (0.929, 0.955, and 0.781, respectively). Reference limits for serum HE4 in healthy Turkish women was determined as 28.9 - 62.4 pmol/L for premenopausal and 23.7 - 152.4 pmol/L for postmenopausal women. Conclusions: In the diagnosis of ovarian cancer, HE4 had higher sensitivity, as a single tumor marker. The sensitivity of HE4 and ROMA index in postmenopausal women was higher than premenopausal women for detecting ovarian cancer.

CA125; HE4; ROMA index; Ovarian cancer.

[1] Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J.: “Cancer statistics”. CA Cancer J. Clin., 2007, 57, 43.

[2] Anderson M.R., Goff B.A., Lowe K.A., Scholler N., Bergan L., Drescher CW., et al.: “Use of a symptom index, CA125 and HE4 to predict ovarian cancer”. Gynecol. Oncol., 2010, 116, 378.

[3] Shuang Y., Hui-jie Y., Shu X., Yi-Xi B.: “Diagnostic value of HE4 for ovarian cancer: a meta-analysis”. Clin. Chem. Lab. Med., 2012, 50, 1439.

[4] Wu L., Dai Z.Y., Qian Y.H., Shi Y., Liu F.J., Yang C.: “Diagnostic value of serum human epididymis protein 4 in ovarian carcinoma”. Int. J. Gynecol. Cancer 2012, 22, 1106.

[5] Sharma S.: “Tumor markers in clinical practice: General principles and guidelines”. Indian J. Med. Paediatr. Oncol., 2009, 30, 1.

[6] Kabawat S.E., Bast R.C., Welch W.R., Knapp R.C., Colvin R.B.: “Im-munopathologic characterization of a monoclonal antibody that rec-ognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types”. Am. J. Clin. Pathol., 1983, 79, 98.

[7] Lenhard M, Stieber P, Hertlein L, Kirschenhofer A., Fürst S., Mayr D., et al.: “The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the dif-ferential diagnosis of ovarian masses”. Clin. Chem. Lab. Med., 2011, 49, 2081.

[8] Escudero J.M., Auge J.M., Filella X., Torne A., Pahisa J., Molina R.: “Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonma-lignant diseases”. Clin. Chem., 2011, 57, 1534.

[9] Skates S.J., Menon U., MacDonald N., Rosenthal A.N., Oram D.H., Knapp R.C., et al.: “Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women”. J. Clin. Oncol., 2003, 21, 206s.

[10] Sjovall K., Nilsson B., Einhorn N.: “The significance of serum CA 125 elevation in malignant and nonmalignant diseases”. Gynecol. Oncol., 2002, 85, 175.

[11] Moore R.G., Miller M.C., Steinhoff M.M., Skates S.J., Lu K.H., Lambert-Messerlian, G., et al.: “Serum HE4 levels are less fre-quently elevated than CA125 in women with benign gynecologic disorders”. Am. J. Obst. Gynecol., 2012, 206, 351

[12] Moore R.G., McMeekin D.S., Brown A.K., DiSilvestro P., Miller M. C., Allard W.J., et al.: “A novel multiple marker bioassay utiliz-ing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass”. Gynecol. Oncol., 2009, 112, 40.

[13] Huhtinen K., Suvitie P., Hiissa J., Junnila J., Huvila J., Kujari H., et al.: “Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts”. Br. J. Cancer, 2009, 100, 1315.

[14] Moore R.G., Brown A.K., Miller M.C., Badgwell D., Lu Z., Allard

W. J., et al.: “Utility of a novel serum tumor biomarker HE4 in pa-tients with endometrioid adenocarcinoma of the uterus”. Gynecol. Oncol., 2008, 110, 196.

[15] Simmons A.R., Baggerly K., Bast R.C. Jr.: “The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas”. Oncology, 2013, 27, 548.

[16] Jacobs I.J., Menon U.: “Progress and challenges in screening for early detection of ovarian cancer”. MCP, 2004, 3, 355.

[17] Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T., et al.: “The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass”. Gy-necol. Oncol., 2008, 108, 402.

[18] Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., Grudzinskas J. G.: “A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer”. Br. J. Obstet. Gynaecol., 1990, 97, 922.

[19] Moore R.G., Jabre-Raughley M., Brown A.K., Robison K.M., Miller M. C., Allard W.J., et al.: “Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass”. Am. J. Obstet. Gynecol., 2010, 203, 228.e1.

[20] Sandri M.T., Bottari F., Franchi D., Boveri S., Candiani M., Ronzoni S., et al.: “Comparision of HE4, CA125 and ROMA algoritm in women with a pelvic mass”. Gynecol. Oncol., 2013,128, 233.

[21] Montagnana M., Danese E., Ruzzenente O., Bresciani V., Nuzzo T., Gelati M., et al.: “The ROMA (Risk of Ovarian Malignancy Algo-rithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?” Clin. Chem. Lab. Med., 2011, 49, 521.

[22] Van Gorp T., Cadron I., Despierre E., Daemen A., Leunen K., Amant F., et al.: “HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algoritm”. Br. J. Cancer, 2011, 104, 863.

[23] Yurkovetsky Z., Skates S., Lomakin A., Nolen B., Pulsipher T., Mod-ugno F., et al.: “Development of a multimarker assay for early detection of ovarian cancer”. J. Clin. Oncol., 2010, 28, 2159.

[24] Molina R., Escudero J.M., Auge J.M., Filella X., Foj L., Torné A., et al.: “HE4 a novel tumour marker for ovarian cancer:comparision with CA125 and ROMA algoritm in patients with gynaecological diseases”. Tumor Biol., 2011, 32, 1087.

[25] Anastasi E., Granato T., Marchei G.G., Viggiani V., Colaprisca B., Comploj S., et al.: “Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women”. Tumour Biol., 2010, 31, 411.

[26] Hallamaa M., Suvitie P., Huhtinen K., Matomäki J., Poutanen M., Perheentupa A.: “Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women”. Gynecol. Oncol., 2012, 125, 667.

[27] Moore R.G., Miller M.C., Eklund E.E., Lu K.H., Bast R.C. Jr, Lam-bert-Messerlian G.: “Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age”. Am. J. Ob-stet. Gynecol., 2012, 206, 349 e1.

[28] Bolstad N., Oijordsbakken M., Nustad K., Bjerner J.: “Human epi-didymis protein 4 reference limits and natural variation in a Nordic reference population”. Tumour Biol., 2012, 33, 141.

[29] Yang J., Sa M., Huang M., Yang J., Xiang Z., Liu B., et al.: “The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay”. Clin. Biochem., 2013, 46, 1705.

[30] Kalapotharakos G., Asciutto C., Henic E., Casslén B., Borgfeldt C., et al.: “High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer”. J Ovarian Res 2012, 5, 20.

[31] Trudel T., Tetu B., Gregoire J., Plante M., Renaud M.C., Bachvarov D., et al.: “Human epididymis protein (HE4) and ovarian cancer prognosis”. Gynecol. Oncol., 2012, 127, 511.

[32] Hellstrom I., Heagerty P.J., Swisher E.M., Liu P, Jaffar J., Agnew K., Hellstrom K.E., et al.: “Detection of HE4 protein in urine as a biomarker for ovarian neoplasms”. Cancer Lett., 2010, 296, 43.